Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 19NIH 8NETWORK 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 5Esophageal Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Pathologic Complete Response 2Fallopian Tube Neoplasms 2Adenocarcinoma of Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thymoma 1Testicular Neoplasms 1Recurrence 1Ovarian Neoplasms 1Non-squamous Cell Non-Small Cell Lung Cancer 1Non-Squamous Non-Small Cell Lung Cancer 1Nasopharyngeal Carcinoma 1Lung Neoplasms 1HER2 Positive Breast Cancer 1Endometrial Neoplasms 1EGFR Positive Non-small Cell Lung Cancer 1Carcinoma, Ovarian Epithelial 1

Interventions

veliparib 1avelumab 1Gemcitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Testicular Neoplasms × Carboplatin × Clear all
NCT02860819 2021-03-03

Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer

National Cancer Institute, Slovakia

Phase 2 Completed
15 enrolled
Genitourinary

Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡